Pathogenesis of Idiopathic Myelofibrosis: A Review

References

• Dameshek, W. (1951). Some speculations on the myeloproliferative syndromes. Blood, 6, 372–376.
   PubMed Web of Science ®Google Scholar
• Dougan, L. E., Matthews, M. L. V. and Armstrong, B. K. (1981). The effects of diagnostic review on the estimated incidence of lymphatic and haematopoietic neoplasms in Western Australia. Cancer, 48, 866–872.
   PubMed Web of Science ®Google Scholar
• Mesa, R. A., Tefferi, A., Jacobsen, S. J., Wollan, P. C. and Silverstein, M. N. (1997). The incidence and epidemiology of essential thrombocythaemia and agnogenic myeloid metaplasia: an Olmstead Country study. Blood, 90 (suppl), 347a.
   Google Scholar
• Ward, H. P. and Block, M. H. (1971). The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with myeloproliferative syndrome. Medicine (Baltimore), 50, 357–420.
   PubMed Web of Science ®Google Scholar
• Reilly, J. T. (1997). Idiopathic meylofibrosis: pathogenesis, natural history and management. Blood Reviews, 11, 233–242.
   PubMed Web of Science ®Google Scholar
• Thiele, J., Kvasnicka, H. M., Werden, C., Zanovich, R., Diehl, V. and Fischer, R. (1996). Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythaemia and variables of prognostic impact. Leuk. Lymph. 22, 303–317.
   PubMed Web of Science ®Google Scholar
• Rawson, R., Parker, F. and Jackson, H. (1941). Industrial solvents as possible etiologic agents in myeloid metaplasia. Science, 93, 541.
   PubMedGoogle Scholar
• Hu, H. (1987). Benzene-associated myelofibrosis. Ann. Int. Med., 106, 171–173.
   PubMed Web of Science ®Google Scholar
• Honda, Y., Delzell, E. and Cole, P. (1995). An updated study of mortality among workers at a petroleum manufacturing plant. J. Occupational. and Environmental Medicine, 37, 194–200.
   PubMed Web of Science ®Google Scholar
• Visfeldt, J. and Andersson, M. (1995). Pathoanatomical aspects of malignant haematological disorders among Danish patients exposed to thorium dioxide. APMIS, 103, 29–36.
   PubMed Web of Science ®Google Scholar
• Anderson, R. E., Hoshino, T. and Yamamoto, T. (1964). Myelofibrosis with myeloid metaplasia in survivors of the atomic bomb in Hiroshima. Ann. Int. Med., 60, 1–18.
   PubMed Web of Science ®Google Scholar
• Jacobson, R. J., Salo, A. and Fialkow, P. J. (1978). Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood, 51, 189–194.
   PubMed Web of Science ®Google Scholar
• Lucas, G. S., Padua, R. A., Masters, G. S., Oscier, D. and Jacobs, A. (1989). The application of X chromosome gene probes to the diagnosis of myeloproliferative disease. Brit. J. Haematol. 72, 530–533.
   PubMed Web of Science ®Google Scholar
• Kreipe, H., Jaquet, K., Felgner, J., Radzun, H.-J. and Parwaresch, M. R. (1991). Clonal granulocytes and marrow cells in the cellular phase of agnogenic myeloid metaplasia. Blood, 78, 1814–1817.
   PubMed Web of Science ®Google Scholar
• El-Maallem, H. and Fletcher, J. (1977). Impaired neutrophil function and myeloperoxidase deficiency in myeloid metaplasia. Brit. J. Haematol., 37, 323–329.
   PubMed Web of Science ®Google Scholar
• Perianin, A., Labro-Bryskier, M. I., Marquetty, C. and Hakim, J. (1984). Glutathione reductase and nitroblue tetrazolium reduction deficiencies in neutrophils of patients with primary idiopathic myelofibrosis. Clin. Exp. Immunol., 57, 244–248.
   PubMed Web of Science ®Google Scholar
• Didisheim, P. and Bunting, D. (1966). Abnormal platelet function in myelofibrosis. American Journal of Clinical Pathology, 45, 566–573.
   PubMed Web of Science ®Google Scholar
• Kuo, C.-Y., Van Voolen, A. and Morrison, A. N. (1972). Primary and secondary myelofibrosis: its relationship to ‘PNH-like defect’. Blood, 6, 875–880
   Google Scholar
• Veer, A., Kosciolek, B. A., Bauman, A. W. and Rowley, P. T. (1979). Acquired haemoglobin H disease in idiopathic myelofibrosis. Am. J. Hematol., 6, 199–206.
   PubMed Web of Science ®Google Scholar
• Silverstein, M. N., Brown, A. L. and Linman, J. W. (1973). Idiopathic myeloid metaplasia: its evolution into acute leukaemia. Arch. Int. Med., 132, 709–712.
   PubMed Web of Science ®Google Scholar
• Reilly, J. T., Barnett, D., Dolan, G., Forrest, P., Eastham, J. and Smith, A. (1993). Characterisation of an acute mictromegakaryocytic leukaemia: evidence for the pathogenesis of myelofibrosis. Brit. J. Haematol., 83, 58–62.
   PubMed Web of Science ®Google Scholar
• Garcia, S., Miguel, A., Miguel, A., Linares, M., Navarro, M. and Colomina, P. (1989). Idiopathic myelofibrosis terminating in erythroleukemia. Am. J. Hematol., 32, 70–71.
   PubMed Web of Science ®Google Scholar
• Polliack, A., Prokocimer, M. and Matzner, Y. (1980). Lymphoblastic leukemic transformation (lymphoblastic crisis) in myelofibrosis and myeloid metaplasia. Am. J. Hematol., 9, 211–220.
   PubMed Web of Science ®Google Scholar
• Hernández, J. M., San Miguel, J. K., González, M., Orfao, A., Cañizo, M. C., Bascones, C., Hernández, J. and López Borrasca, A. (1992). Development of acute leukaemia after idiopathic myelofibrosis. J. Clin. Pathol, 45, 427–430.
   PubMed Web of Science ®Google Scholar
• Han, Z. C., Briere, J., Nedellec, G., Abgrall, J. F., Senzebe, L., Parent, D. and Guern, G. (1988). Characteristics of circulating megakaryocyte progenitors (CFU-MK) in patients with myelofibrosis. Eur. J. Hematol., 40, 130–135.
   PubMed Web of Science ®Google Scholar
• Hibbin, J. A. A., Njoku, O. S., Matutes, E., Lewis, S. M. and Goldman, J. M. (1984). Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders. Brit. J. Haematol., 57, 495–503.
   PubMed Web of Science ®Google Scholar
• Carlo-Stella, C., Cazzola, M., Gasner, A., Barosi, G., Dezza, L., Meloni, F., Pedrazzoli, P., Hoelzer, D. and Ascari, E. (1987). Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. Blood, 70, 1014–1019.
   PubMed Web of Science ®Google Scholar
• Moliterno, A. R., Hankins, W. D. and Spivak, J. L. (1998). Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. New Eng. J. Med., 338, 572–580.
   PubMed Web of Science ®Google Scholar
• Ritchie, A., Gotoh, A., Gaddy, J., Braun, S. E. and Broxmeyer, H. E. (1997). Thrombopoietin upregulates the promoter conformation of p53 in a proliferative-independent manner coincident with a decreased expression of Bax: potential mechanisms for enhancing effects. Blood, 90, 4394–4402.
   PubMed Web of Science ®Google Scholar
• Greenberg, B. R., Woo, L. and Veomett, I. C. (1987). Cytogenetics of bone marrow fibroblastic cells in idiopathic chronic myelofibrosis. Brit. J. Haematol., 66, 487–490.
   PubMed Web of Science ®Google Scholar
• Castro-Malaspina, H., Gay, R. E. and Thanwar, S. L. (1982). Characteristics of bone marrow fibroblast colony forming cells and their progeny in patients with myeloproliferative disorders. Blood, 59, 1046–1056.
   PubMed Web of Science ®Google Scholar
• Anderson, J. E., Sale, G., Appelbaum, F. R., Chauncey, T. R. and Strob, R. (1997). Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Brit. J. Haematol., 98, 1010–1016.
   PubMed Web of Science ®Google Scholar
• Guardiola, P., Esperou, H., Cazals-Hatem, D., Ifrah, N., Jouet, J.-P., Buzyn, A., Sutton, L., Gratecos, N., Tilly, H., Lioure, B. and Gluckman, E. (1997). Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. Brit. J. Haematol, 98, 1004–1009.
   PubMed Web of Science ®Google Scholar
• Reilly, J. T., Wilson, G., Barnett, D., Watmore, A. and Potter, A. (1994). Karyotypic and ras gene mutational analysis in idiopathic myelofibrosis. Brit. J. Haematol, 88, 575–581.
   PubMed Web of Science ®Google Scholar
• Reilly, J. T., Snowden, J. A., Spearing, R. L., Fitzgerald, P. M., Jones, N., Watemore, A. and Potter, A. (1997). Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Brit. J. Haematol, 98, 96–102.
   PubMed Web of Science ®Google Scholar
• Dupriez, B., Morel, P., Demory, J. L., Lai, J. L., Simon, M., Plantier, I. and Bauters, F. (1996). Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood, 88, 1013–1018.
   PubMed Web of Science ®Google Scholar
• Trautmann, U., Rubbert, A., Gramatzki, M., Henschke, F. and Gebhart, E. (1992). Multiple chromosomal changes and karyotypic evolution in a patient with myelofibrosis. Cancer Genetics and Cytogenetics, 61, 6–10.
   PubMedGoogle Scholar
• Demory, J. L., Dupriez, B., Fenaux, P., Lai, J. L., Beuscart, R., Jouet, J. P., Deminatti, M. and Bauters, F. (1988). Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases. Blood, 72, 855–859.
   PubMed Web of Science ®Google Scholar
• Morris, C. M., Cochrane, J. M., Benjes, S. M., Crossen, P. E. and Fitzgerald, P. H. (1991). Molecular definition of interstitial deletions of chromosome 13 in leukaemic cells. Genes, Chromosomes and Cancer, 3, 455–460.
   PubMed Web of Science ®Google Scholar
• Lebowtiz, P., Papac, R. and Ghosh, P. K. (1990). Impaired retinoblastoma susceptibility (Rb) gene expression in agnogenic myeloid metaplasia. Blood, 76 (suppl. 1), 236a.
   Google Scholar
• Pastore, C., Nomdedeu, J., Volpe, G., Guerrasio, A., Rege Cambrin, G., Parvis, G., Pautasso, M., Daglio, C., Mazza, U., Saglio, G. and Gaidano, G. (1995). Genetic analysis of chromosomal 13 deletions in bcr/abl negative chronic myeloproliferative disorders. Genes, Chromosomes and Cytogenetics, 14, 106–111.
   PubMed Web of Science ®Google Scholar
• Gardiner, A. C., Corcoran, M. M., Ibbotson, R. E., Potter, A. and Oscier, D. G. (1998). An analysis of chromosome 13q14 deletions in idiopathic myelofibrosis using FISH and Southern-based hybridisation. Brit. J. Haematol, 101 (suppl 1), 106.
   Google Scholar
• La Starza, K., Wlodarska, I., Aventin, A., Falzetti, D., Crescenzi, B., Martelli, M. F., Van den Berghe, H. and Mecucci, C. (1998). Molecular delineation of 13q deletion boundaries in 20 patients with myeloid malignancies. Blood, 91, 231–237.
   PubMed Web of Science ®Google Scholar
• Brown, A. G., Ross, F. M., Dunne, E. M., Steel, C. M. and Weit-Thompson, E. M. (1993). Evidence for a new suppressor locus (DBM) in human B-cell neoplasia telomeric to the retinoblastoma gene. Nat. Genet., 3, 67–72.
   PubMed Web of Science ®Google Scholar
• Mertens, F., Johansson, B., Heim, S., Kristoffersson, U. and Mitelman, F. (1991). Karyotypic patterns in chronic myeloproliferative disorders: report on 74 cases and review of literature. Leukemia, 5, 214–220.
   PubMed Web of Science ®Google Scholar
• Asimakopoulos, F. A. and Green, A. R. (1996). Deletions of chromosome 20q and the pathogenesis of myeloproliferative disorders. Brit. J. Haematol, 95, 219–226.
   PubMed Web of Science ®Google Scholar
• Gahrton, G., Friburg, K., Lindsten, J. and Zech, L. (1978). Duplication of part of the long arm of chromosome 1 in myelofibrosis terminating in acute myeloblastic leukemia. Hereditas, 88, 1–5.
   PubMed Web of Science ®Google Scholar
• Donti, E., Tabilio, A., Bocchini, F., Falzetti, F., Martelli, M. F., Grignani, F. and Donti, G. V. (1990). Partial trisomy 1q in idiopathic myelofibrosis. Leuk. Res., 14, 1035–1040.
   PubMed Web of Science ®Google Scholar
• Zanke, B., Squire, J., Griesser, H., Henry, M., Suzuki, H., Patterson, B., Minden, M. and Mak, T. W. (1994). A hematopoietic protein tyrosine phosphatase (HePTP) gene that is amplified and overexpressed in myeloid malignancies maps to chromosome 1q32.1. Leukaemia, 8, 236–244.
   PubMed Web of Science ®Google Scholar
• Thiele, J., Kuemmel, T., Sander, C. and Fischer, R. (1991). Ultrastructure of the bone marrow tissue in so-called primary (idiopathic) myelofibrosis-osteomyelosclerosis (agnogenic myeloid metaplasia). 1. Abnormalities of megakaryopoiesis and thrombocytes. J. Submicroscopic. Cytol. Pathol., 23, 93–107.
   PubMed Web of Science ®Google Scholar
• Burkhardt, R., Bartl, R., Beil, E., Demmler, K., Hoffman, E. and Kronseder, A. (1974). Myelofibrosis-osteomyelosclerosis syndrome: review of literature in histomorphology. Advances. in the Biosciences, Dahlem Workshop on Myelofibrosis-Osteomyelosclerosis Syndrome, Berlin, pp. 9–54.
   Google Scholar
• Den Ottolander, G. J., Te Velde, J., Brederoo, P., Geraedts, J. P. M., Slee, T. H. Th. J., Willemze, R., Zwaan, F. E., Haak, H. I., Muller, H. P. and Bieger, R. (1979). Megakaryoblastic leukaemia (acute myelofibrosis): a report of three cases. Brit. J. Haematol., 42, 9–20.
   PubMed Web of Science ®Google Scholar
• Jantunen, E., Hnninen, A., Naukkarinen, A., Vornanen, M. and Lahtinen, R. (1994). Gray platelet syndrome with splenomegaly and signs of extramedullary hematopoiesis: a case report with review of the literature. Am. J. Hematol., 46, 218–224.
   PubMed Web of Science ®Google Scholar
• Charron, D., Robert, L., Couty, M. C. and Binet, J. L. (1979). Biochemical and histological analysis of bone marrow collagen in myelofibrosis. Brit. J. Haematol., 41, 151–161.
   PubMed Web of Science ®Google Scholar
• Gay, S., Gay, R. E. and Prchal, J. T. (1984). Immunological studies of bone marrow fibrosis. Myelofibrosis and the Biology of Connective Tissue (Ed. by. Berk, P., Castro-Malaspina. H. and Wasserman, L. R.), pp. 291–306. Alan R. Liss.; New York.
   Google Scholar
• Reilly, J. T., Nash, J. R. G., Mackie, M. J. and McVerry, B. A. (1995). Endothelial cell proliferation in myelofibrosis. Brit. J. Haematol., 60, 625–630.
   Web of Science ®Google Scholar
• Apaja-Sarkkinen, M., Autio-Harmainen, H., Alavaikko, M., Risteli, J. and Risteli, L. (1986). Immunohistological study of basement membrane proteins and type III procollagen myelofibrosis. Brit. J. Haematol., 63, 571–580.
   PubMed Web of Science ®Google Scholar
• Reilly, J. T., Dolan, G., Brindley, L., Kay, M., Fielding, S., Kennedy, A. and Smith, A. (1995). Bone marrow and serum connective tissue polypeptides in idiopathic myelofibrosis. Clin. Lab. Haematol., 17, 35–39.
   PubMedGoogle Scholar
• Reilly, J. T., Nash, J. G. R., Mackie, M. J. and McVerry, B. A. (1985). Immuno-enzymatic detection of fibronectin in normal and pathological haematopoietic tissue. Brit. J. Haematol., 59, 497–504.
   PubMed Web of Science ®Google Scholar
• Soini, Y., Kamel, D., Apaja-Sarkkinen, M., Virtanen, I. and Lehto, V.-P. (1993). Tenascin immunoreactivity in normal and pathological bone marrow. J. Clin. Pathol., 46, 218–221.
   PubMed Web of Science ®Google Scholar
• Reilly, J. T. and Nash, J. G. R. (1988). Vitronectin (serum spreading factor): its localisation in normal and fibrotic tissue. Journal of Clinical Pathology, 59, 1269–1272.
   Web of Science ®Google Scholar
• Castro-Malaspina, H., Rabellino, E. M., Yen, A., Nachman, R. L. and Moore, M. A. S. (1981). Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts. Blood, 57, 781–787.
   PubMed Web of Science ®Google Scholar
• Heldin, C.-H., Westermark, B. and Wasteson, A. (1979). Platelet-derived growth factor purification and partial characterisation. Proc. Nat. Acad. Sci. USA, 76, 3722–3726.
   PubMed Web of Science ®Google Scholar
• Bernabei, P. A., Arcangeli, A., Casini, M., Grossi, A., Padovani, R. and Ferrini, P. R. (1986). Platelet-derived growth factor(s) mitogenic activity in patients with myeloproliferative disease. Brit. J. Haematol., 63, 353–357.
   PubMed Web of Science ®Google Scholar
• Katoh, O., Kimura, A. and Kuramoto, A. (1988). Platelet-derived growth factor is decreased in patients with myeloproliferative disorders. Am. J. Haematol., 27, 276–280.
   PubMed Web of Science ®Google Scholar
• Dolan, G., Forrest, P. L., Eastham, J. M. and Reilly, J. T. (1991). Reduced platelet PDGF levels in idiopathic myelofibrosis. Brit. J. Haematol., 78, 586–588.
   PubMed Web of Science ®Google Scholar
• Gersuk, G., Carmel, R. and Pattengale, P. K. (1989). Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders. Blood, 74, 2330–2334.
   PubMed Web of Science ®Google Scholar
• Theile, J., Braeckel, C., Wagner, S., Falini, B., Dienemann, D., Stein, H. and Fischer, R. (1991). Macrophages in normal human bone marrow and in chronic myeloproliferative disorders: an immunohistochemical and morphometric study by a new monoclonal antibody (PG-M1) on trephine biopsies. Virchows Archiv A. Pathological. Anatomy and Histopathology, 421, 33–39.
   Google Scholar
• Gersuk, G. M., Carmel, R., Pattamakom, S., Challita, P. M., Rabinowitz, A. P. and Pattengale, P. K. (1993). Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. Nat. Immun., 12, 136–151.
   PubMedGoogle Scholar
• Roberts, A. B. and Sporn, M. B. (1990). The transforming growth factor-betas. In: Peptide Factors and their Receptors (Ed. By Sporn, M. B. and Roberts, A. B.). Springer, New York.
   Google Scholar
• Fava, R. A., Casey, T. T., Wilcox, J., Pelton, R. W., Moses, H. L. and Nanney, L. B. (1990). Synthesis of transforming growth factor-β1 by megakaryocytes and its localisation to megakaryocytes and platelet α-granules. Blood, 76, 1946–1955.
   PubMed Web of Science ®Google Scholar
• Varga, J., Rosenbloom, J. and Jimenez, S. A. (1987). Transforming growth factor-β (TGF-β) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal and human dermal fibroblasts. Biochem. J., 247, 597–604.
   PubMed Web of Science ®Google Scholar
• Nakamura, T., Okuda, S., Miller, D., Ruoslahti, E. and Border, W. (1990). Transforming growth factor-β (TGF-β) regulates production of extracellular matrix (ECM) components by glomerular epithelial cells. Kid. Int., 37, 221–225.
   Web of Science ®Google Scholar
• Pearson, C. A., Pearson, D., Shibahara, S., Hofsteenage, J. and Chiquet Ehrismann, R. (1988). Tenascin: cDNA cloning and induction by TGF-β. EMBO Journal, 7, 2977–2981.
   PubMed Web of Science ®Google Scholar
• Martyré, M. C., Magdelenat, H., Bryckaert, M. C., Laine-Bidron, C. and Calvo, F. (1991). Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-β in patients with myelofibrosis and myeloid metaplasia. Brit. J. Haematol., 77, 80–86.
   PubMed Web of Science ®Google Scholar
• Zauli, G., Visani, G., Catani, L., Vianelli, N., Gugliotta, L. and Capitani, S. (1993). Reduced responsiveness of bone marrow megakaryocyte progenitors to platelet-derived transforming growth factor-β1, produced in normal amount, in patients with essential thrombocythaemia. Brit. J. Haematol., 83, 14–20.
   PubMed Web of Science ®Google Scholar
• Terui, T., Niitsu, Y., Mahara, K., Fugisaki, Y., Urushizaki, Y., Mogi, Y., Kohgo, Y., Watanabe, N., Ogura, M. and Saito, H. (1990). The production of transforming growth factor-β in acute megakaryoblastic leukemia and its possible implications in myelofibrosis. Blood, 75, 1540–1548.
   PubMed Web of Science ®Google Scholar
• Johnson, J. B., Dalal, B. I., Israels, S. J., Oh, S., McMillan, E., Begleiter, A., Michaud, G., Israels, L. G. and Greenberg, A. H. (1995). Deposition of transforming growth factor-β in the marrow in myelofibrosis, and the intracellular localization and secretion of TGF-β by leukemic cells. Am. J. Clin. Pathol., 103, 574–582.
   PubMed Web of Science ®Google Scholar
• Titius, B. R., Thiele, J., Schaefer, H., Kreipe, H. and Fischer, R. (1994). Ki-S1 and proliferating cell nuclear antigen expression of bone marrow macrophages. Acta Haem., 91, 144–149.
   PubMedGoogle Scholar
• Rameshwar, P., Denny, T. N., Stein, D. and Gascon, P. (1994). Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines. Potential. role for interleukin-1 and TGF-beta. J. Immunol., 153, 2819–1830.
   PubMed Web of Science ®Google Scholar
• Rameshwar, P., Chang, V. T. and Gascón, P. (1996). Implication of CD44 in adhesion-mediated overproduction of TGF-β and IL-1 in monocytes from patients with bone marrow fibrosis. Brit. J. Haematol., 96, 22–29.
   Web of Science ®Google Scholar
• Cashman, J. D., Eaves, A. C., Raines, E. W., Ross, R. and Eaves, C. J. (1990). Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. I. Stimulatory role of a variety of mesenchymal cell activators and inhibitory role of TGF-β, Blood, 75, 96–101.
   PubMed Web of Science ®Google Scholar
• Le Bousse-Kerdilés, M.-C., Chevillard, S., Charpentier, A., Romquin, N., Clay, D., Smadja-Jaffe, F., Praloran, V., Dupriez, B., Demory, J.-L., Jasmin, C. and Martyró, M.-C. (1996). Differential expression of transforming growth factor-/I, basic fibroblast growth factor, and their receptors in CD34+ haematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood, 88, 4534–4546.
   PubMed Web of Science ®Google Scholar
• Dalley, A., Smith, J. M., Reilly, J. T. and MacNeil, S. (1996). Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: evidence for a role of extracellular calmodulin in fibroblast proliferation. Brit. J. Haematol, 93, 856–862.
   PubMed Web of Science ®Google Scholar
• Martyré, M. C., Le Bousse-Kerdiles, M.-C., Romquin, N., Chevillard, S., Praloran, V., Demory, J.-L. and Dupriez, B. (1997). Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Brit. J. Haematol., 97, 441–448.
   PubMed Web of Science ®Google Scholar
• Murate, T., Yamashita, K., Isogai, C., Suzuki, H., Ichihara, M., Hatano, S., Nakahara, Y., Kinoshita, T., Nagasaka, T., Yoshida, S., Komatsu, N., Miura, Y., Hotta, T., Fujimoto, N., Saito, H. and Hayakawa, T. (1997). The production of tissue inhibitors of metallproteinases (TIMPs) in megakaryopoiesis: possible role of platelet- and megakaryocyte-derived TIMPs in bone marrow fibrosis. Brit. J. Haematol., 99, 181–189.
   PubMed Web of Science ®Google Scholar
• Rondeau, E., Soal-Celigny, P., Dhermy, D., Wroclans, M., Brousse, N., Bernard, J. F. and Boivin, P. (1983). Immune disorders in agnogenic myeloid metaplasia: relation to fibrosis. Brit. J. Haematol., 53, 467–475.
   PubMed Web of Science ®Google Scholar
• Gordon, B. R., Colman, M., Kohen, P. and Day, N. K. (1981). Immunologic abnormalities in myelofibrosis with activation of the complement system. Blood, 58, 904–910.
   PubMed Web of Science ®Google Scholar
• Caligaris Cappio, F., Vigliani, R., Novarino, A., Camussi, G., Campana, D. and Gavosto, F. (1981). Idiopathic myelofibrosis: a possible role for immunecomplexes in the pathogenesis of bone marrow fibrosis. Brit. J. Haematol., 49, 17–21.
   PubMed Web of Science ®Google Scholar
• Lewis, C. M. and Pegrum, G. D. (1972). Immunocomplexes in myelofibrosis: a possible guide to management. British Journal of Haematology, 39, 233–239.
   Web of Science ®Google Scholar
• Leoni, P., Ruploi, S., Salvi, A., Sambo, P., Cinciripini, A. and Gabrielli, A. (1993). Antibodies against terminal galactosyl α(1–3) galactose epitopes in patients with idiopathic myelofibrosis. Brit. J. Haematol, 85, 313–319.
   PubMed Web of Science ®Google Scholar
• Jack, F. R., Smith, S. R. and Saunders, P. W. G. (1994). Idiopathic myelofibrosis: anaemia may respond to low-dose dexamethasone. Brit. J. Haematol., 87, 876–884.
   PubMed Web of Science ®Google Scholar
• Pietrasanta, D., Clavio, M., Vallebella, E., Beltrami, G., Cavaliere, M. and Gobbi, M. (1997). Long-lasting effect of cyclosporin-A on anaemia associated with idiopathic myelofibrosis. Haematologica, 82, 458–459.
   PubMed Web of Science ®Google Scholar
• Rozman, C., Giralt, M., Feliu, E., Rubio, D. and Cortes, M.-T. (1991). Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer, 67, 2658–2663.
   PubMed Web of Science ®Google Scholar